In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shire acquires Noven's MethyPatch; Noven reacquires rights

Executive Summary

Shire Pharmaceuticals (central nervous system, cancer, and anti-infective drugs) has acquired Noven Pharmaceuticals' (transdermal drug delivery) MethyPatch (methylphenidate), a once-daily patch to treat attention deficit hyperactivity disorder (ADHD), which has been awaiting FDA approval since June 2002.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Marketing (Licensing)
    • Product Purchase

Related Companies